Landos Biopharma (LABP) executive Oakes received 1,677,251 units

Insider transactions reported

Gregory Oakes (executive at Landos Biopharma Inc., LABP) reported that they received 1,677,251 units on Jun 20, 2022.

Reporting person

Oakes Gregory

Options and other derivatives

Holdings before and after

• Employee Stock Option (right to buy): 0 to 1,677,251 direct

Footnotes from the filing

1. 1. 25% of the shares of common stock underlying this option will vest and become exercisable on June 20, 2023 and the remaining shares of common stock underlying this option will vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ